



## Luxturna (voretigene neparvovec-rzyl) Clinical Coverage Criteria

### Overview

Biallelic RPE65 mutation-associated retinal dystrophy is a serious and sight-threatening autosomal recessive genetic disorder. Clinical diagnoses that are caused by biallelic mutations in the RPE65 gene include Leber congenital amaurosis Type 2 (LCA2) and retinitis pigmentosa type 20 (RP20). Leber congenital amaurosis manifests in early life with severe vision impairment; whereas patients with retinitis pigmentosa undergo a gradual course of night blindness and visual field loss. There are approximately 1,000 to 3,000 patients with biallelic RPE65 mutation-associated retinal dystrophy in the United States.

On December 19, 2017, the U.S. Food & Drug Administration (FDA) approved Luxturna (Spark Therapeutics, Inc.), an adeno-associated virus vector-based gene therapy, for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy (Package Insert - Luxturna, Spark Therapeutics, Inc., Philadelphia, PA available at: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna>).

- Genetic testing is required to confirm the presence of pathogenic(s) variants in the RPE65 gene. By definition, pathogenic variant(s) must be present in both copies of the RPE65 gene to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy.
- Patients must have sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography and/or ophthalmoscopy.
- Use in infants under 12 months of age is not recommended because of potential dilution or loss of Luxturna after administration due to the active retinal cells proliferation occurring in this age group.

Luxturna works by delivering a normal copy of the RPE65 gene directly to retinal cells. These retinal cells then produce the normal protein that converts light to an electrical signal in the retina to restore patient's vision loss. Luxturna uses a naturally occurring adeno-associated virus, which has been modified using recombinant DNA techniques, as a vehicle to deliver the normal human RPE65 gene to the retinal cells to restore vision.

Luxturna is administered by subretinal injection to each eye on separate days within a close interval, but no fewer than 6 days apart. It is recommended that patients receive systemic oral corticosteroids equivalent to prednisone at 1 mg/kg/day (maximum of 40 mg/day) for a total of 7 days (starting 3 days before administration of Luxturna to the first eye), and followed by tapering the dose during the next 10 days. If the corticosteroid taper following Luxturna administration to the first eye is not complete three days prior to the planned Luxturna administration to the second eye, then the corticosteroid regimen for the second eye replaces the taper for the first eye (Package Insert. Luxturna, Spark Therapeutics, Inc., Philadelphia, PA. 2017).

U.S. Food & Drug Administration (FDA) approval of Luxturna on December 19, 2017, was based on the results of three clinical trials:

- NCT 00516477, a Phase 1, open label dose-escalation safety study in 12 children and adults, aged 8-44 years with RPE65-associated Leber's congenital amaurosis were given a subretinal injection of Luxturna in one eye.

- NCT 01208389, a Phase 1 follow-on study in which the 12 participants from the Phase 1 study received Luxturna in the uninjected, contralateral eye. Improvements in functional vision have been sustained for 3 years—with observations ongoing (Bennett et al., 2016).
- NCT 00999609, a Phase 3 safety and efficacy study in which 31 patients ranging in age from 4 to 44 years were randomized in a 2:1 ratio to either the Luxturna treatment group or the observational control group. One participant from each group withdrew after consent, before intervention, leaving an intent-to-treat population of 20 intervention and nine control participants. The participants were followed for one year for the primary efficacy endpoint of change in multi-luminance mobility testing (MLMT). A median MLMT score change of two (2) was observed in the Luxturna treatment group, while a median MLMT score change of zero (0) was observed in the control group, when using both eyes or the first-treated eye. An MLMT score change of two or greater is considered a clinically meaningful benefit for functional vision. No product-related serious adverse events or deleterious immune responses occurred. The FDA concluded that the submitted data provided sufficient evidence of effectiveness for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. This conclusion is based on improvement in functional vision, as determined by a significant difference in MLMT score change from Baseline to Year 1 between the Luxturna treatment and control groups, when using either both eyes ( $p=0.0001$ ) or the first-treated eyes ( $p=0.003$ ) (FDA, December 18, 2017 Summary Basis for Regulatory Action - Luxturna).

The durability of response is currently unknown given the recent FDA-approval of this therapy. Improvements in functional vision have been sustained through 3 years post-administration, with observation ongoing (Bennett et al., 2016). All participants enrolled in the Phase 1 and Phase 3 clinical studies for Luxturna are enrolled in a long-term observational study and will be followed for 15 years (NCT 03602820). To further evaluate the long-term safety, the manufacturer is also conducting a 5-year post-marketing observational study involving patients treated with Luxturna (NCT 03597399). Enrollment will start with the first patient treated following FDA approval and continue through March 31, 2020.

At this time, Luxturna is only administered at Ocular Gene Therapy Treatment Centers selected by Spark Therapeutics (<https://mysparkgeneration.com/hcp-support.html>).

## Policy

This Policy applies to the following Fallon Health products:

- Commercial
- Medicare Advantage
- MassHealth ACO
- NaviCare
- PACE

Fallon Health follows guidance from the Centers for Medicare and Medicaid Services (CMS) for organization (coverage) determinations for Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and guidance in the Medicare manuals are the basis for coverage determinations. When there is no NCD, LCD, LCA or manual guidance, Fallon Health Clinical Coverage Criteria are used for coverage determinations.

Medicare does not have an NCD for Luxturna (voretigene neparvovec-rzyl). National Government Services does not have an LCD or LCA for Luxturna (MCD search 06/22/2021).

For plan members enrolled in NaviCare and PACE plans, Fallon Health follows Medicare guidance for coverage determinations. When there is no Medicare guidance or if the plan member does not meet medical necessity criteria in Medicare guidance, Fallon Health Clinical Coverage Criteria are used for coverage determinations. Fallon Health's Clinical Coverage Criteria are developed in accordance with the definition of Medical Necessity in 130 CMR

450.204 and are therefore no more restrictive than MassHealth Medical Necessity Guidelines. In the event that neither Medicare nor Fallon Health have coverage criteria, Fallon Health will follow MassHealth Guidelines for Medical Necessity Determination (Fallon Health Weinberg PACE will follow New York State Medicaid Guidance). Each PACE plan member is assigned to an Interdisciplinary Team. When there is no Medicare or State Medicaid Agency guidance, the PACE plan member's Interdisciplinary Team is responsible for coverage determinations.

For MassHealth ACO members, Fallon Health Clinical Coverage Criteria are used for coverage determinations. Fallon Health's Clinical Coverage Criteria are developed in accordance with the definition of Medical Necessity in 130 CMR 450.204 and are therefore no more restrictive than MassHealth Medical Necessity Guidelines.

Prior authorization is required for Luxturna. This prior authorization is separate from any prior authorization that may be required for the member's inpatient or outpatient encounter. Submission of medical records documenting all of the medical necessity criteria is required on all requests for Luxturna.

Luxturna is considered medically necessary when medical record documentation confirms all of the following criteria are met:

1. The member is at least 12 months of age on date of first administration.
2. The member has a clinical diagnosis of a biallelic RPE65 mutation-associated retinal dystrophy (e.g., Leber congenital amaurosis Type 2 (LCA2) and retinitis pigmentosa type 20 (RP20).
3. Genetic testing has confirmed the presence of biallelic RPE65-mediated inherited retinal dystrophy (homozygotes or compound heterozygotes). A copy of the genetic test results must be submitted.
4. Luxturna will be administered at a designated Ocular Gene Therapy Treatment Center (<https://mysparkgeneration.com/hcp-support.html>) and a retina specialist from the designated Ocular Gene Therapy Treatment Center has confirmed that the member has sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy. Documentation of one of the following is required:
  - a. An area of retina within the posterior pole of >100 µm thickness shown on OCT;
  - b. ≥ 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or
  - c. Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent.
5. Luxturna will be administered per FDA Prescribing Information Dosage and Administration:
  - a. The recommended dose of Luxturna for each eye is  $1.5 \times 10^{11}$  vector genomes (vg), administered by subretinal injection in a total volume of 0.3 mL.
  - b. Perform subretinal administration of Luxturna to each eye on separate days within a close interval, but no fewer than 6 days apart.
  - c. Recommend systemic oral corticosteroids equivalent to prednisone at 1 mg/kg/day (maximum of 40 mg/day) for a total of 7 days (starting 3 days before administration of Luxturna to the first eye), and followed by tapering the dose during the following 10 days. The same corticosteroid dosing regimen applies for the administration of Luxturna to the second eye. If the corticosteroid taper following Luxturna administration to the first eye is not complete three days prior to the planned Luxturna administration to the second eye, then the corticosteroid regimen for the second eye replaces the taper for the first eye
6. The member has not:
  - a. Used high-dose (>7500 retinol equivalent units [or >3300 IU] per day of vitamin A) retinoid compounds in the past 18 months; or
  - b. Had intraocular surgery in the past 6 months.

## Exclusions

- Use in infants less than 12 months of age is not recommended because of potential dilution or loss of Luxturna after administration due to the active retinal cells proliferation occurring in this age group.
- The safety and efficacy of repeat administration of Luxturna have not been evaluated.

## Coding

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage or reimbursement.

### ICD-10 Diagnosis Codes

ICD-10-CM	Description
H35.50	Unspecified hereditary retinal dystrophy
H35.52	Pigmentary retinal dystrophy
H35.54	Dystrophies primarily involving the retinal pigment epithelium

### HCPCS Codes

Code	Description
67036	Vitrectomy, mechanical, pars plana approach
C9770	Vitrectomy, mechanical, pars plana approach, with subretinal injection of pharmacologic/biologic agent
J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes

Modifiers (RT/LT) should be included on the same line as the CPT code to identify the eye to which administration of Luxturna occurred.

Outpatient hospitals and ambulatory surgical centers submitting claims for administering Luxturna for **Medicare and commercial plan members** should use HCPCS code C9770 effective January 1, 2021.

Outpatient hospitals and ambulatory surgical centers submitting claims for administering Luxturna **MassHealth ACO plan members** should use CPT code 67036. MassHealth does not recognize C-HCPCS codes.

As noted in the FDA approved labeling, the recommended dose of Luxturna for each eye is 1.5 x 10<sup>11</sup> (150 billion) vector genomes, administered by subretinal injection in a total volume of 0.3 mL.<sup>2</sup> With the J code descriptor of 1 billion vector genomes, it is appropriate to indicate 150 units of J3398 on the claim form.

### MassHealth Acute Hospital Carve-Out Drugs List

Luxturna is on the MassHealth Acute Hospital Carve-out Drugs List. In accordance with **MassHealth Managed Care Entity Bulletin 42**, Fallon Health requires hospitals to take the following actions with respect to drugs and biologics on the MassHealth Acute Hospital Carve-Out List for MassHealth ACO plan members:

1. Drugs and biologics on the MassHealth Acute Hospital Carve-Out Drugs List require prior authorization. The hospital must obtain prior authorization for the drug or biologic from Fallon Health. This prior authorization is separate from any prior authorization that may be required for the member's inpatient or outpatient encounter.
2. A drug or biologic designated by MassHealth as a carve-out drug must not be included on the facility/institutional claim that the hospital submits for the plan member's inpatient or outpatient encounter.
3. The hospital must instead submit a separate claim for the carve-out drug on a facility/institutional claim form (i.e., UB-04). (In other words, the drug is the only item on the

UB-04 claim.) The charge reported on the claim must be the “hospital’s actual acquisition cost” for the drug.\*

4. The claim for the carve-out drug must be reported with revenue code 0636 (Drugs requiring detailed coding), the HCPCS code for the drug, the National Drug Code (NDC) for the drug, and number of units of the carve-out drug administered to the member.
5. The hospital must also include the following as separate attachments to the claim:
  - a. A statement of the hospital’s actual acquisition cost of the carve-out drug (as defined below) used to treat the member; and
  - b. A copy of the invoice(s) for the carve-out drug from the drug manufacturer, supplier, distributor, or other similar party or agent; and
  - c. Other additional documentation that the Plan deems necessary to evidence the hospital’s actual acquisition cost of the carve-out drug.

\* For purposes of this requirement, the “hospital’s actual acquisition cost” of the carve-out drug is defined as follows:

*“...the hospital’s invoice price for the drug, net of all on-or-off invoice reductions, discounts, rebates, charge backs and similar adjustments that the hospital has or will receive from the drug manufacturer or other party for the drug that was administered to the member including any efficacy, outcome, or performance-based guarantees (or similar arrangements), whether received pre-or post-payment.”*

The MassHealth Acute Hospital Carve-out Drugs List is available at:

<https://masshealthdruglist.ehs.state.ma.us/MHDL/>. This list may be updated from time to time.

Claims for Luxturna (J3398) for MassHealth ACO and NaviCare plan members must be submitted with the 11-digit NDC Code. When reporting an NDC, all of the following NDC information is required:

- NDC Qualifier (F4)
- NDC Unit of Measure Qualifier (F2, GR, ME, UN, ML)
- NDC quantity

## References

1. U.S. Food and Drug Administration (FDA). December 18, 2017 Summary Basis for Regulatory Action – Luxturna. Available at: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna>. Accessed June 18, 2021.
2. Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, Pierce E, Sallum J, Larsen M, Stieger K, Preising M, Weleber R, Yang P, Place E, Liu E, Schaefer G, DiStefano-Pappas J, Elci OU, McCague S, Wellman JA, High KA, Reape KZ. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. *Am J Ophthalmol*. 2019 Mar;199:58-70. doi: 10.1016/j.ajo.2018.09.024. Epub 2018 Sep 28.
3. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. *N Engl J Med*. 2008 May 22;358(21):2240-8.
4. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. *Lancet*. 2009 Nov 7;374(9701):1597-605. Erratum in: *Lancet*. 2010 Jan 2;375(9708):30.
5. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying GS, Ziviello C, Acerra C,

- Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. *Mol Ther.* 2010 Mar;18(3):643-50.
6. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM. AAV2 gene therapy readministration in three adults with congenital blindness. *Sci Transl Med.* 2012 Feb 8;4(120):120ra15.
  7. Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, Elci OU, Chung DC, Sun J, Wright JF, Cross DR, Aravand P, Cyckowski LL, Bennicelli JL, Mingozzi F, Auricchio A, Pierce EA, Ruggiero J, Leroy BP, Simonelli F, High KA, Maguire AM. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. *Lancet.* 2016 Aug 13;388(10045):661-72.
  8. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet.* 2017 Aug 26;390(10097):849-860. doi: 10.1016/S0140-6736(17)31868-8. Epub 2017 Jul 14. Erratum in: *Lancet.* 2017 Aug 26;390(10097):848.
  9. Package Insert. Luxturna, Spark Therapeutics, Inc., Philadelphia, PA. Available at: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna>. Accessed June 18, 2021.
  10. Sengillo JD, Justus S, Tsai YT, Cabral T, Tsang SH. Gene and cell-based therapies for inherited retinal disorders: An update. *Am J Med Genet C Semin Med Genet.* 2016 Dec;172(4):349-366.
  11. Gao J, Hussain RM, Weng CY. Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence. *Clin Ophthalmol.* 2020 Nov 13;14:3855-3869.

## Policy history

Origination date: 09/01/2021  
Approval(s): Technology Assessment Committee: 06/22/2021 (policy origination).

*Not all services mentioned in this policy are covered for all products or employer groups. Coverage is based upon the terms of a member's particular benefit plan which may contain its own specific provisions for coverage and exclusions regardless of medical necessity. Please consult the product's Evidence of Coverage for exclusions or other benefit limitations applicable to this service or supply. If there is any discrepancy between this policy and a member's benefit plan, the provisions of the benefit plan will govern. However, applicable state mandates take precedence with respect to fully-insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, federal mandates will apply to all plans.*